Build the system. Unlock the future.
Who We Are
Global Health Ecosystems is a not-for profit, systems architecture and market shaping organisation focused on catalysing investment for the global health research and innovation sector and unlocking its potential through:
We support global health research and development funders, policymakers, innovators and advocates to design efficient, systemic solutions that connect LMIC-led priorities, incentives, financing, and leadership strengthening across health areas and regions.
Our Team
Andrew Tuttle
Chief Executive Officer
With nearly two decades of experience across the public, private, and third sectors, Andrew specialises in catalysing high-impact investment for a range of global health initiatives. He served as the Director of Research and Chief Strategy Officer at Impact Global Health where he led sector-shaping research on the impact of investing in health R&D. He also has a proven track record of mobilising blended resources and managing complex portfolios for organisations like the Gates Foundation, MSI Reproductive Choices and Chemonics. Andrew brings a combination of strategic leadership, technical credibility, and practical delivery experience, with a proven track record of translating complex evidence into actionable programmes and policy-relevant outputs. Currently a DrPH candidate at LSHTM, Andrew marries academic rigour with executive expertise to unlock the potential of global health systems.
Harriet Bell
Director, Strategy & Engagement
Harriet brings over 25 years’ experience across strategic communications, digital engagement, product development and business strategy, including senior executive roles at Impact Global Health, The Lancet and as a member of the executive team of Chapter Zero, a network supporting FTSE 350 board members on climate leadership. She has a strong track record of engaging partners, advocacy communities and media to amplify evidence, adapt global findings to regional political and fiscal contexts, and support institutional leaders to communicate investment cases effectively for sustained uptake and use. Harriet has developed innumerable evidence-based advocacy materials for parliamentarians and global health investors across Africa, Europe and Asia and for major global health conferences and convenings.
Yasir Samir
Director, Leadership Strengthening
Yasir drives GHE's board and leadership efficacy, organisational culture and change management initiatives. He brings a wealth of cross-industry experience in inclusive leadership and transforming organisational culture through diversity, equity and a focus on our humanity. His more than 25 years' experience spans executive leadership, information technology and organisational culture across the health and development sectors, including for the NHS Modernisation Agency, Healthdirect Australia, the BMJ, the Center for Global Development and the Health and Care Professions Council. By combining expertise in ethical leadership with a deep understanding of the nuances of leading health, development and research organisations, and solid business strategy, Yasir ensures that leadership structures are resilient, effective, compassionate and fit for purpose for the global health research and investment sector.
Vanessa Candeias
Director, Systems Research
& Impact
Vanessa brings more than two decades of experience at the intersection of global health, economics and policy, with particular strengths in partnership-building, high-level stakeholder engagement, and translating evidence into political and financial action. She delivered the health and economic impact research portfolio at Impact Global Health, including landmark work quantifying the health and economic returns on investment in global health R&D. She has extensive experience shaping investment narratives for governments, donors, and multilateral institutions. Previously a senior executive at the World Economic Forum, she led global work on the health and economic impact of non-communicable diseases and catalysed major cross-sector partnerships, including with CEPI, while convening CEOs, Ministers, researchers, and international organisations to advance global health priorities.
Our Advisory Board
Olayinka Fagbayi
Olayinka Fagbayi is Vice President and Head of Impact at the Global Health Investment Corporation (GHIC), a mission-driven investment firm and pioneer of impact investing in global health. She leads the firm's impact strategy across its Global Health and Health Security portfolios, embedding impact stewardship into investment decision-making and portfolio management.
Olayinka's career has been defined by building systems that connect capital, science, and public purpose. At the International AIDS Vaccine Initiative (IAVI), she served as Senior R&D Program Director, directing global research and development programs and consortia, and bringing together partners across governments, industry, academia, and civil society to accelerate the translation of health products for those who need them most.
Stefanie Fairholme
Stefanie Fairholme is Managing Director and Chief Investment Officer for Capital Solutions at British International Investment (BII), the UK’s development finance institution.
She oversees the strategy, portfolio construction and monitoring of all catalytic capital investment pools, with a mandate to deliver impact in nascent industries, pioneering business models and innovative financial structures that mobilise private finance into emerging and frontier economies.
Prior to BII, Stefanie held various investment leadership roles at the Global Energy Alliance for People and Planet (GEAPP) and The Rockefeller Foundation. In the earlier half of her career, Stefanie spent more than a decade in investment banking in New York and London.
Nada O. Hanafi
Nada Hanafi is a regulatory strategist and health equity champion transforming how MedTech innovations reach patients in underserved communities. As Founder of MedTech Strategy Advisors, she guides life science companies from concept to commercialization through pragmatic regulatory pathways, evidence generation, and de-risking strategies.
With 12+ years at FDA , Nada co-founded the Health of Women programme, the Network of Experts, and the Patient Preference Initiative—advancing regulatory efficiency and inclusive innovation. She also served as a liaison to FDA's Office of Women's Health, Office of Minority Health and advised NIH's Office of Research on Women's Health.
Nada co-founded MedTech Color (advancing representation in MedTech) and serves on steering committees for the Gates Foundation's Innovation Equity Forum, Reagan-Udall Foundation, and Milken Institute.
Andrew McDowell
Andrew has over 20 years of financial services leadership experience, specialising in enterprise risk management and strategic transformation. Currently serving as Senior Risk Business Partner for the Private Markets business within L&G Asset Management, Andrew is adept at deploying risk frameworks tailored to complex investment landscapes and diverse industries.
Andrew brings a distinct strength in guiding specific change management and transaction lifecycles. He has provided risk advisory support for the wind-down of businesses, strategic divestments, and the analysis of financial plans and client impacts during mergers. Notably, he has advised on the risks associated with transforming operations through outsourced third-party administration and the integration of housing subsidiary businesses. Andrew combines this technical acumen with award-winning leadership in Diversity, Equity, & Inclusion, championing a risk culture that supports sustainable business maturity.
Marie-Evelyne Pétrus-Barry
Marie-Evelyne is an international human rights and development expert from Guadeloupe and Guinea who brings 30 years of experience in high-level political affairs and management of development programmes in multicultural and humanitarian settings.
She has recently ended six years as Regional Director for Africa at the International Planned Parenthood Federation where she led organisational change and improved governance, sustainability and coordinated efficiency in 43 African countries.
Her formidable career in the UN spanned diverse roles including: Resident Coordinator and UNDP Representative in Gabon, Director of the UN Information Center in South Africa, Regional Representative for Central Africa at the UN Office of the High Commissioner for Human Rights in Cameroon, and Chief of the Advocacy and Outreach Unit for the UN mission in Haiti.
She studied African-American history and African literature, focusing her research on people of African descent, the links between the diaspora and Africa and decolonisation. She speaks French, English, Portuguese, Fulani and Creole.
Tom Murdoch
Tom is a Partner at Stone King where he specialises in charity and not-for-profit law and is particularly known for his expertise in charitable status, the development of novel charitable purposes and the governance and control of complex charity structures, including charity spin-offs from the state. He acts for a wide variety of charities and social enterprises in various areas, including public interest information, social investment, educational and campaigning organisations; academic, professional and learned institutions; and heritage, science and environmental/conservation charities.
Tom advises on contentious and charity-law compliance issues, structural re-organisations, amendment of royal charters, trading, mergers and restricted funds, special trusts and endowments.
What We Do
1.
Identify & Diagnose
Identify and diagnose risks, levers, transition pathways and players within global health research and innovation ecosystems. Who are the key actors, landscape-wide? What levers will deliver the biggest systemic change?
2.
Convene & Align
Convene and align funders, developers, civil society, academia and industry around a co-created view of the ecosystem – setting priorities, connecting dots, and building consensus. Once we are all looking at the same map, navigation becomes easier, and a common language of change develops.
3.
Build Investment Blueprints
Build investment blueprints and facilitate market shaping driven by those most impacted, directing a new generation of impact investors to bring to life a more efficient and equitable research ecosystem.
4.
Catalyse Capital
Blend, mobilise and deploy capital through pooled funds and innovative finance instruments, accelerating impact.
5.
Mature Organisations
Strengthen leadership in recipient organisations, ensuring investments are maximised and flow through institutions that have healthy cultures, suitable governance and effective leaders.
Our Vision
A world where lifesaving health innovations are developed, financed, and delivered justly, equitably and efficiently - driven by systemic investment, sustainable demand, and resilient research ecosystems.
Our Mission
Global Health Ecosystems exists to catalyse systemic change for global health research and innovation, closing critical gaps in financing, market-shaping, leadership, and equitable access for underserved populations.
Architect the future and mobilise catalytic capital.
Partner with GHE to de-risk your global health portfolio, enhance systems and strengthen leadership for better health outcomes.